Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Chimerix

$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones jumped by more than 750 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall…

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

6 Stocks To Watch Amid Monkeypox Outbreak

6 Stocks To Watch Amid Monkeypox Outbreak

A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

12 Health Care Stocks Moving In Monday's Intraday Session

Chimerix Shares Plummet After Divesting Its Only Marketed Product For Over $300M

Emergent BioSolutions Inc (NYSE:EBS) has agreed to acquire Chimerix Inc's (NASDAQ:CMRX) exclusive worldwide rights to Tembexa (brincidofovir), the first FDA-approved antiviral for all age groups for smallpox. "It exemplifies our thoughtful M&A strategy as part of our 2024 growth plan and positions us better to deliver value for our shareholders," said Robert Kramer, president…

Chimerix's Earnings Outlook

Chimerix (NASDAQ:CMRX) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Chimerix will report an earnings per share (EPS) of $-0.33.

Chimerix Confirms Ongoing Negotiations With BARDA On Smallpox Medicine Contract

In its SEC filing, Chimerix Inc (NASDAQ:CMRX) announced that it had been aware of unusual trading activity in the Company's common stock. The Company believes the unusual trading activity may be attributable to statements regarding smallpox antiviral development and procurement contained in the Fiscal Year 2023 Congressional Justification for the Public Health…

inkl

Read news from The Economist, FT, and more,
with one subscription

Looking Into Chimerix's Return On Capital Employed

Looking Into Chimerix's Return On Capital Employed

Benzinga Pro data, Chimerix (NASDAQ:CMRX) reported Q4 sales of $46.00 thousand. Earnings fell to a loss of $39.50 million, resulting in a 112.81% decrease from last quarter.

Chimerix: Q4 Earnings Insights

Chimerix: Q4 Earnings Insights

Chimerix (NASDAQ:CMRX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Electronic Arts

Truist Securities

Hims Hers Health

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

339,009 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play